Half-Year 2022 Financial and Clinical Trials Update
Roche Group development pipeline
RG3502
RG6026
Kadcyla + T
Kadcyla + T
glofitamab+chemo
tiragolumab + T
Phase III (10 NMES + 43 Als)
Venclexta
2L+ HER-2+ PD-L1+ mBC
HER-2+ eBC high-risk
2L+ DLBCL
r/r MM t(11:14)
RG6013
Hemlibra¹
RG7601
Venclexta + azacitidine
1L MDS
RG6026
tiragolumab +T
1L esophageal cancer
1L PD-L1+ NSCLC
Lunsumio (mosunetuzumab) +
lenalidomide
RG6396
Gavreto¹
2L+ FL
RG7596
RG7828
Polivy³
RG6058
tiragolumab + T
tiragolumab + T
locally advanced esophageal cancer
stage III unresectable 1L NSCLC
Lunsumio (mosunetuzumab) +
Polivy
2L+ DLBCL
RG7828
Lunsumio (mosunetuzumab)4
RG6321
Susvimo (PDS) 1
RG7853
Alecensa
ALK+ NSCLC adj
Vabysmo (faricimab) 1
RG3648
Xolair
food allergy
RG7716
crovalimab
PNH
Vabysmo (faricimab) 1
RG6107
RG6354
zinpentraxin alfa (PRM-151)
IPF
crovalimab
aHUS
Gazyva
lupus nephritis
RG6114
inavolisib (mPI3K alpha inh)
1L HR+ MBC
RG7159
Gazyva
giredestrant (SERD)
1L ER+/HER2-mBC
Gazyva
RG6171
giredestrant (SERD)
RG7440
giredestrant (SERD) + Phesgo
ipatasertib+abiraterone
Tecentriq + platinum chemo
ER+ BC adj
1L ER+/HER2+ BC
Xofluza
RG6152
Xofluza
Tecentriq
1L CRPC
NSCLC neoadj
NMIBC, high risk
gantenerumab
RG1450
gantenerumab
membranous nephropathy
systemic lupus erythematosus
influenza, pediatric (0-1 year)
influenza direct transmission
prodromal to mild Alzheimer's
early Alzheimer's
RG6152
RG56413+
RG6412
Xofluza
RG1569
Actemra4
RG7916
Evrysdi¹
Roche
Registration US & EU (4 NMES + 8 Als)
glofitamab²
Ronapreve²
mild to moderate hemophilia A
3L+ DLBCL
RET+ MTC, TC
1L DLBCL
3 L+ FL
WAMD
DME
WAMD
influenza, pediatric
SARS-CoV-2 hospitalised
COVID-19 pneumonia
SMA pediatric <2months
1
Ocrevus higher dose
Tecentriq
RCC adj
RG1594
Ocrevus SC
Tecentriq+cabozantinib
RCC adv
RG7446
Tecentriq+cabozantinib
T± chemo
T + capecitabine or carbo/gem
T + paclitaxel
2L NSCLC
SCCHN adj
RG6042
RG6168
RG6356
tominersen
RMS & PPMS
RMS & PPMS
Huntington's
Approved in US, filed in EU
2 Filed in the EU
3 Approved in EU
4 Approved in EU, filed in US
Enspryng
myasthenia gravis
delandistrogene moxeparvovec (SRP-9001)
DMD
T + Avastin
T + chemo
1L TNBC
TNBC adj
HCC adj
RG7845
fenebrutinib
RMS
T=Tecentriq
PDS-Port Delivery System with ranibizumab
RG7845
fenebrutinib
PPMS
Susvimo (PDS)
DME
1L MUC
RG6321
Susvimo (PDS)
DR
New Molecular Entity (NME)
Tecentriq SC
Tecentriq
T+ lurbinectedin
2L NSCLC
ctDNA+ high-risk MIBC
RG7716
1L maintenance SCLC
Susvimo (PDS)
Vabysmo (faricimab)
Vabysmo (faricimab)
WAMD, 36-week
BRVO
CRVO
Additional Indication (Al)
Oncology/Hematology
Immunology
Metabolism
Neuroscience
Ophthalmology
Other
Status as of July 21, 2022
Infectious Diseases
75View entire presentation